Amphotericin B-associated hyperbilirubinemia: Case report and review of the literature

Pharmacotherapy

Volumn 26, Issue 7 I, 2006, Pages 1011-1017

  Olin, Jacqueline L ^a   Spooner, Linda M ^b  

^a RUTGERS UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Amphotericin B; Amphotericin B lipid complex; Hyperbilirubinemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; CIPROFLOXACIN; FLUCONAZOLE; METRONIDAZOLE;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ADULT; BONE METASTASIS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CARDIOMYOPATHY; CASE REPORT; CITROBACTER FREUNDII; COLON PERFORATION; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; DRUG FORMULATION; DRUG INDUCED DISEASE; ENTEROCOCCUS; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MEDLINE; REVIEW; SEPSIS; STAPHYLOCOCCUS EPIDERMIDIS; THORACOCENTESIS;

EID: 33745712751     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.7.1011     Document Type: Review

References (25)

1. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
2. Maddrey WC. Drug-induced hepatotoxicity 2005. J Clin Gastroenterol 2005;39:S83-9.
3. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38(suppl 2):S44-8.
4. Pratt DS, Kaplan MM. Evaluation of liver function. In: Kasper DL, Braunwald EB, Fauci AS, et al, eds. Harrison's principles of internal medicine, 16th ed. New York: McGraw Hill, 2005:1813-16.
5. Mattox TW, Reiter PD. Parenteral nutrition. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Co., 2005:2579-613.
6. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003;37:415-25.
7. Miller MA. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984;131:1245-7.
8. Carnecchia BM, Kurtzke JF. Fatal toxic reaction to amphotericin B in cryptococcal meningo-encephalitis. Ann Intern Med 1960;53:1027-35.
9. Gill J, Sprenger HR, Ralph ED, Sharpe MD. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother 1999;33:683-5.
10. Ellis M, Shamoon A, Gorka W, Zwaan F, al-Ramadi B. Severe hepatic injury associated with lipid formulations of amphotericin B [online exclusive article]. Clin Infect Dis 2001;32:e87-9.
11. da Silva LP, Amaral JM, Ferreira NC. Which is the most appropriate dosage of liposomal amphotericin-B (AmBisome) for the treatment of fungal infections in infants of very low birth weight [letter]? Pediatrics 1993;91:1217-18.
12. Mohan UR, Bush A. Amphotericin B-induced hepatorenal failure in cystic fibrosis. Pediatr Pulmonol 2002;33:497-500.
13. Koren G, Lau A, Kenyon CF, Kroppert D, Klein J. Clinical course and pharmacokinetics following a massive overdose of amphotericin B in a neonate. Clin Toxicol 1990;28:371-8.
14. Kan VL, Bennett JE, Amantea MA, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholates in healthy male volunteers. J Infect Dis 1991;164:418-21.
15. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
16. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
17. Ringden O, Jonsson V, Hansen M, Tollemar J, Jacobsen N. Severe and common side-effects of amphotericin B lipid complex (Abelcet) [letter]. Bone Marrow Transplant 1998;22:733-4.
18. Furebring M, Oberg G, Sjolin J. Side-effects of amphotericin B lipid complex (Abelcet) in the Scandinavian population [letter]. Bone Marrow Transplant 2000;25:341-3.
19. Lackner H, Urban C. Which is the most appropriate dosage of liposomal amphotericin-B (AmBisome) for the treatment of fungal infections in infants of very low birth weight [letter]? Pediatrics 1993;91:1218.
20. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
21. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66.
22. Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000;25:879-84.
23. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
24. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005;41:301-7.
25. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.